Navigation Links
Kedem Pharmaceuticals Engages a FDA Compliant Contract Formulation Development Company for the Production of KDM-1102 Clinical Materials
Date:1/4/2012

PHOENIX, Jan. 4, 2012 /PRNewswire/ -- Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery is pleased to announce that it has signed a contract with a GMP pharmaceutical FDA compliant formulation development company, Corealis Pharma, Inc. for the production of the phase I clinical supplies of KDM-1102, the Company's second lead therapeutic drug. The KDM-1102 drug is a new sublingual formulation of propanolol. The formulation development of the KDM-1102 drug is now completed and can be produce in large volume.

"We are pleased with the progress we have been making in our development program on KDM-1102, our Second lead therapeutic drug for cardiovascular and anxiety attacks," said Dr. Hassan Salari, Kedem Pharmaceuticals, President & CEO.

About Sublingual Technology

The Company's sublingual formulation is designed to enhance drugs to be delivered to the body without the need for injection. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly and efficiently. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver break down. It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection. The technology may apply to over 40 major drugs which all can benefit from this route.

About Kedem Pharmaceuticals Inc. (KDMP.ob) is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. The Company has several other drugs under development for fast and convenient delivery. These include drugs for anxiety attack, osteoporosis, sleeping disorder
'/>"/>

SOURCE Kedem Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Merz Pharmaceuticals Receives J-Code For Xeomin® (incobotulinumtoxinA)
2. Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
3. Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy
4. Auxilium Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
5. MAP Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Jazz Pharmaceuticals to Hold Investor Conference Call on January 5 to Discuss 2012 Financial Guidance and Azur Pharma Transaction
7. Radient Pharmaceuticals Announces Reverse Stock Split
8. Idenix Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
9. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11. Endo Pharmaceuticals to Present at J.P. Morgan 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
(Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown ... 5, 2011 at 9:30 a.m. (IST) at the TASE Headquarters ... The day will include presentations on the Consumer Healthcare, ... and research and development. Perrigo Company is ...
... PARK, Calif., Oct. 4, 2011 CV Ingenuity, a ... a $16 million Series B round of financing led ... capital firm. Existing investors BioStar Ventures, Synergy Ventures and ... (CVI), which is focused on the development of a ...
Cached Medicine Technology:CV Ingenuity Announces Close of $16 Million Series B Financing Led by NEA 2
(Date:10/19/2014)... working in the garment industry for decades, LunaDress’ dress specialists ... one of the company’s top designers, many ladies like prom ... add beauty to them. Chiffon floor length outfits are also ... selection of 2014 long prom dresses. , As a ... in over 20 popular designs. The company intends to meet ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many kinds ... designs of 2014 mother of the bride dresses ... offered with big discounts, up to 70% off. All ... enjoy this special offer. , Owing to the ... one of the leading brands in the global market. ...
(Date:10/19/2014)... NC (PRWEB) October 19, 2014 ... building program has just been released to the ... the online body building and fitness community. The ... attention of DietsAndFitnessGuides.com's Vin Delmonico prompting an investigative ... experience of hitting what is commonly known as ...
(Date:10/19/2014)... 19, 2014 (HealthDay News) -- New stem cell-based research ... to new treatments, a new study suggests. Scientists ... intestinal tissue in a lab dish. They then transplanted ... studying intestinal disorders, according to the researchers. "This ... and conditions that can cause intestinal failure, from genetic ...
(Date:10/19/2014)... 2014 – The U.S. Government has initiated a ... disease by 2025. However, a workgroup of nearly ... milestones in the U.S. Government,s National Plan to ... increased in scale, and adequately funded in order ... proposals by the workgroup to enlarge and strengthen ...
Breaking Medicine News(10 mins):Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6
... unique variations in the human genetic code among 276 ... ,The 34 so-called single nucleotide polymorphisms, or SNPs, represent ... of the fatal neurodegenerative disease. ,“Although we ... our results seriously narrow the search and bring us ...
... all forms of heart failure, the heart begins to ... fetal heart//. Researchers have known for years that this ... investigators at the University of Pennsylvania School of Medicine ... development regulates the enlargement of heart cells, known as ...
... benefits for breast cancer prevention among women at high risk ... The trials found that the breast cancer risk reduction persists ... used both to treat breast cancer and to prevent it ... of the data on tamoxifen for breast cancer prevention comes ...
... Pharma has been asked to pay $3 million to a ... with its hormone// replacement drug prempro. ,Jennie Nelson ... accusing their drug prempro to have caused breast cancer in ... menopausal women. Nelson has been taking this drug for six ...
... A general practitioner who was accused of prescribing addictive drugs ... General Medical Council. ,Dr. Julien Eden who runs ... of accusations like prescribing sixty sedatives to a teenager with ... of the same drugs later. ,The General Medical ...
... recent study has demonstrated the benefits of multiple low-energy ... can help reduce wrinkles and enhance the appearance, in ... impact of a single high-energy session, with reduced healing ... matter in which electrons are stripped from atoms to ...
Cached Medicine News:Health News:Human Genetic Code for ALS Identified 2Health News:Fetal Heart-Cell Enzyme and Onset of Heart Failure 2Health News:Tamoxifen Yields Long-term Reduction in Breast Cancer Risk 2Health News:Tamoxifen Yields Long-term Reduction in Breast Cancer Risk 3Health News:Multiple Low-energy Plasma Skin Treatments Beneficial in Reducing Facial Wrinkles 2
... Nd:YAG laser system with a wavelength of 1,064 ... superficial as well as red and blue vein ... patients with darker skin types (1 to 6) ... general improvement of skin texture. The handpieces special ...
... The UroVysion Bladder Cancer Kit (UroVysion Kit) ... 7, 17, and loss of the 9p21 locus ... specimens from persons with hematuria suspected of having ... intended for use, in conjunction with and not ...
A Powerful New Quantitative Immunoassay for Monitoring Bladder Cancer Patients. Useful in Monitoring Patients for,Disease Progression and Recurrence....
ARION is a long-pulsed alexandrite laser system with a wavelength of 755 nm...
Medicine Products: